ConvaTec prelim 2025 revenue slightly beats on Infusion Care unit strength

ConvaTec

24/02/2026 07:10

Overview

Medical products firm's 2025 revenue slightly beat analyst expectations, growing 6.5% yr/yr

2025 EBIT missed analyst estimates, declining compared to previous year

Company announced $300 mln share buyback and increased dividend by 13%

Outlook

ConvaTec expects FY26 organic revenue growth excluding InnovaMatrix of 5-7%

Company anticipates FY26 adjusted operating margin of ≥23.0%

ConvaTec upgrades medium-term organic growth target to 6-8% from 2027

Result Drivers

BROAD-BASED GROWTH - ConvaTec achieved broad-based organic revenue growth across all categories, supported by new product launches and operational efficiencies

INFUSION CARE - Infusion Care segment saw a 15.1% revenue increase, driven by strong demand for infusion sets in diabetes and non-diabetes therapies

MARGIN EXPANSION - Adjusted operating margin improved by 110 bps to 22.3%, aided by automation and productivity initiatives

Company press release: ID:nRSX0838Ua

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
Slight Beat*
$2.44 bln
$2.43 bln (18 Analysts)
FY EBIT
Miss
$316 mln
$525.26 mln (18 Analysts)
FY Adjusted EBIT
$544 mln
FY Adjusted EBIT Margin
22.30%
FY Dividend
$0.07
FY EBIT Margin
13.00%


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for ConvaTec Group PLC is GBp315.00, about 38.8% above its February 23 closing price of GBp227.00

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)